Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
July 31 2018 - 4:15PM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of precisely targeted oncology therapies, today
announced that the company will present at the 2018 Wedbush PacGrow
Healthcare Conference in New York. The presentation is scheduled
for Wednesday, August 15, at 8:35 a.m. Eastern Time.
A webcast of the presentation will be available live and for 90
days following the event. The webcast may be accessed via the
conference website and from the investor relations section of the
Corvus website.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of precisely
targeted oncology therapies. Corvus’ lead product candidate,
CPI-444, a small molecule inhibitor of the A2A receptor, is
currently being evaluated in a multicenter Phase 1/1b clinical
trial in patients with various solid tumors. This successive
expansion cohort trial is examining the activity of CPI-444 both as
a single agent and in combination with Genentech’s atezolizumab, an
anti-PD-L1 antibody. Corvus is conducting the trial with Genentech,
a member of the Roche Group, under a clinical trial
collaboration the two companies entered into in October 2015.
In May 2017, Corvus and Genentech expanded the collaboration
and are now conducting a trial of CPI-444 and atezolizumab in
patients with non-small cell lung cancer (NSCLC) who have failed
prior therapies with anti-PD-(L)1 and platinum based chemotherapy.
Corvus is evaluating a second product candidate, CPI-006, a
humanized monoclonal antibody directed against CD73, in a
multicenter Phase 1/1b clinical trial in patients with various
solid tumors. For more information,
visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:Julie NormartW2O pure
+1-415-946-1087jnormart@w2ogroup.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024